443
Participants
Start Date
March 30, 2019
Primary Completion Date
January 26, 2021
Study Completion Date
February 16, 2021
Tirzepatide
Administered SC
Oral antihyperglycemic medication (OAM)
Oral antihyperglycemic medication (OAM): Sulfonylurea, biguanide, alpha-glucosidase inhibitor, thiazolidinedione, glinide, or sodium-glucose cotransporter type 2 inhibitor.
Akaicho Clinic, Chiba
Kashiwa hospital, Kashiwa
Yuri Ono Clinic, Sapporo
Manda Hospital, Sapporo
Miyanomori Hospital, Sapporo
Ikeda Hospital, Amagasaki
Nakamoto Naika Clinic, Mito
Naka Memorial Clinic, Naka
Ohishi Naika Clinic, Tsuchiura
Takai Naika Clinic, Kamakura
Tsuruma Kaneshiro Diabetes Clinic, Yamato
Yokohama Minoru Clinic, Yokohama
H.E.C. Science Clinic, Yokohama
Takatsuki Red Cross Hospital, Takatsuki
Otsu City Hospital, Ōtsu
Wakakusa Clinic, Shimotsuke
Seiwa Clinic, Adachi-ku
HDC Atlas Clinic, Chiyoda City
Asahi Life Foundation Adult Disease Research Center, Chuo-ku
Nihonbashi Sakura Clinic, Chuo-ku
Tokyo-Eki Center-building Clinic, Chuo-ku
Tokyo Center Clinic, Chuo-ku
Tokyo Clinical Trial Centre Fukuwa Clinic, Chuo-ku
Kanno Naika, Mitaka
Shinjuku Research Park Clinic, Shinjuku-Ku
Futata Tetsuhiro Clinic, Fukuoka
Morinaga Ueno Clinic, Kumamoto
Jinnouchi Hospital, Kumamoto
Saiseikai Noe Hospital, Osaka
Kitada Clinic, Osaka
Kansai Denryoku Hospital, Osaka
Abe Diabetes Clinic, Ōita
Shizuoka City Shizuoka Hospital, Shizuoka
Suruga Clinic, Shizuoka
Eli Lilly and Company
INDUSTRY